Session-aware quotes · provider delays vary · Not financial advice
NeutralLOW severityEarnings18d ago

Exelixis outlines zanza CRC launch plans as 2026 revenue guidance midpoint is lowered by $50M

Reported by Seeking Alpha · seekingalpha.com · August 6, 2026

$EXEL
Neutral read

Exelixis (EXEL) Q2 2026 earnings call recap: lowered revenue guidance on slower NET ramp, cabo trends, zanzalintinib CRC filing, and catalysts—read now.

What the tape says

What to watch: EXEL (EXEL) cut guidance — a cut like this often precedes further estimate revisions across the sector.

Amount
$50 million

Market reaction today: $EXEL +0.87%

Tone and severity are deterministic keyword classification — not a prediction, a member vote, or a recommendation. Figures are extracted from the headline as published. Wook does not republish Seeking Alpha's reporting.

Your read

Discussion

No one has weighed in yet. Start the discussion on this story.

More coverage on these names

Headline and link are attributed to Seeking Alpha. Wook of Wall Street is an independent research tool and is not affiliated with Seeking Alpha. Nothing here is financial advice or a recommendation — research and educational content only.